Spaarne Gasthuis Stichting

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Atrial fibrillation3 trials
• Obesity3 trials
• COPD1 trial
• Heart failure1 trial
• Multiple sclerosis1 trial
• Prostate cancer1 trial
• Psoriasis1 trial
• Stroke1 trial

Phase

• Phase 34 trials
• Phase 44 trials
• Phase 22 trials

Status

• Recruiting6 trials
• Active, not recruiting3 trials
• Completed1 trial

Lead sponsor

• AbbVie1 trial
• Acesion Pharma1 trial
• Amgen Inc.1 trial
• Amsterdam UMC Stichting1 trial
• Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)1 trial
• and 5 more

Running trials

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A study to investigate the efficacy, safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation

  2025-520518-79-00· Phase 2· Novartis Pharma AG· Source

• Recruiting

  Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation

  NCT07267949· Phase 2· Acesion Pharma· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· Phase 3· Amgen Inc.· Source

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

  NCT06959095· Phase 3· GlaxoSmithKline· Source

• Recruiting

  Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial

  2024-513092-40-00· Phase 4· Stichting Radboud universitair medisch centrum· Source

• Active, not recruiting

  Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)

  NCT04225312· Phase 4· Amsterdam UMC Stichting· Source

• Active, not recruiting

  DUTCH Weight Control in Atrial Fibrillation Study

  NCT06184633· Phase 4· Rijnstate Hospital· Source

• Recruiting

  Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume castration-sensitive prostate cancer: a randomized Nationwide Study

  2023-506698-36-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation2 recruiting
• COPD1 recruiting
• Heart failure1 recruiting
• Obesity1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

  NCT06333860· Phase 4· AbbVie· Source